A combination of two widely available anti-rheumatic drugs offers the first effective and affordable treatment for patients ...

Idiopathic pulmonary fibrosis (IPF) is a life-threatening disease in which lung tissue becomes scarred, making it hard to ...

IgG4-related disease is a chronic fibroinflammatory condition that can affect virtually any organ system. Glucocorticoid agents are a cornerstone of therapy but are limited by toxic effects, and ...

The Bundibugyo virus, a little known type, previously had caused just two small outbreaks. Now it’s at the center of a ...

No approved therapeutics exist for the virus species causing the outbreak, which has been associated with more than 1,000 ...

Northwestern Medicine scientists have discovered that suppressing excitatory synaptic transmission in a small group of ...

The field of prurigo nodularis has seen landmark updates in the past 5 years, with clinicians expecting more potential ...

The World Health Organization's director reports that five patients have recovered from a rare type of Ebola virus in eastern Congo, where a new treatment center has opened.

Studies of obinutuzumab, a type II anti-CD20 antibody, have shown efficacy in the treatment of hematologic cancers and autoimmune diseases. An evaluation of the efficacy and safety of obinutuzumab in ...

Monthly rifampin-moxifloxacin-minocycline therapy lowers the risk for type 1 reactions in patients with Hansen disease, study shows.

The landmark success of a drug against an ‘undruggable’ cancer is spurring fresh optimism in the quest to treat seemingly untouchable tumour targets. The experimental drug, daraxonrasib, disarms all ...

Crystalys Therapeutics has dosed the first patient with its once daily oral, URAT1 inhibitor dotinurad in its Phase II AMETHYST trial (NCT07535034), designed to assess dotinurad’s effectiveness in ...